Iterum Presents 2 Posters at IDWeek 2025 Conference on UTI Treatment

Iterum Therapeutics will present two posters at IDWeek 2025 conference in Atlanta, GA from October 19-22, 2025. The presentations will focus on urinary tract infections in adult women and the treatment failure risk factors. The company will also conduct a Learning Lounge on October 21, 2025, at 1:15 pm EST.

Iterum Therapeutics plc (Nasdaq: ITRM), a biopharmaceutical company focused on delivering next-generation oral and IV antibiotics, has announced, according to a Stocktitan news release, that it will present two posters at the Infectious Disease Society of America’s IDWeek 2025 conference in Atlanta, GA from October 19-22, 2025. The presentations will focus on urinary tract infections (UTIs) in adult women and the risk factors for treatment failure.

The first presentation, titled "Risk factors for treatment failure in patients with uncomplicated urinary tract infection," will be presented by Dr. Steven I. Aronin on Monday, October 20, 2025, from 12:15 p.m. to 1:30 p.m. at Poster Hall B4-5. The second presentation, "In vitro activity of sulopenem and comparator agents against U.S. Enterobacterales clinical isolates, SENTRY antimicrobial surveillance program, 2023," will also be presented by Dr. Aronin on Tuesday, October 21, 2025, at the same location and time.

In addition to these presentations, Iterum Therapeutics will be conducting a Learning Lounge on Tuesday, October 21, 2025, at 1:15 p.m. EST. The Learning Lounge, titled "An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem," will be led by Drs. Steven I. Aronin and Michael Dunne.

The company's oral antibiotic ORLYNVAH™, a novel oral penem antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs), is expected to be a key focus of these presentations. ORLYNVAH™ has demonstrated potent activity against species of Enterobacterales, including those that encode extended spectrum beta-lactamases (ESBL) or AmpC-type ß-lactamases that confer resistance to third-generation cephalosporins.

Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with both oral and IV formulations. The company has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ for the treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options.

For more information about Iterum Therapeutics and its products, visit their website at www.iterumtx.com.